Previous close | 5.24 |
Open | 5.28 |
Bid | 5.40 x 100 |
Ask | 5.47 x 100 |
Day's range | 5.28 - 5.77 |
52-week range | 2.68 - 8.22 |
Volume | |
Avg. volume | 327,819 |
Market cap | 172.321M |
Beta (5Y monthly) | 4.04 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.83 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 21.00 |
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting- -Company Granted Subsequent Type-B Clinical Meeting with FDA in Second Quarter to Continue to Discuss Pathway to BLA- -Capricor Management to Host Virtual Investor Webcast to Discuss Latest Program Updates on Monday, April 29 at
The average of price targets set by Wall Street analysts indicates a potential upside of 218.2% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.